Leal Therapeutics raises $30M
Leal Therapeutics announced a Series A round of $30M on 17 August 2026. The company operates in HealthTech and is based in United States. It was founded by Asa Abeliovich, Founder & CEO.
Founder
Asa Abeliovich
Founder & CEO, Leal Therapeutics
Outreach angles
- -Abeliovich previously founded Prevail Therapeutics, a Parkinson's gene therapy company Eli Lilly acquired in 2021 for roughly $1.04 billion.
- -He published landmark 2016 Nature research linking cellular trafficking defects to Parkinson's pathology while a tenured Columbia professor.
- -Leal just closed a $30M Series A extension to launch a Phase 1b/2a trial of LTX-001 in schizophrenia.
Signals
Series AHealthcareDeep TechRegulated IndustrySecond-Time Founder
Round details
Company: Leal Therapeutics
Domain: lealtx.com
Amount: $30M
Stage: Series A
Industry: HealthTech
Country: United States
Announced: 17 August 2026
Other HealthTech raises
Recently funded in United States